
Pluristem Therapeutics PSTI
Quarterly report 2026-Q3
added 05-14-2026
Pluristem Therapeutics DPO Ratio 2011-2026 | PSTI
Annual DPO Ratio Pluristem Therapeutics
| 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 | 2012 | 2011 | 2010 | 2009 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 490 | 127 K | 72.9 K | - | - | - | 416 K | 595 K | - | 9.87 K | 91.8 K | 115 K | 51.8 K | - | - | - | - |
All numbers in USD currency
Indicator range from annual reports
| Maximum | Minimum | Average |
|---|---|---|
| 595 K | 490 | 164 K |
Quarterly DPO Ratio Pluristem Therapeutics
| 2026-Q3 | 2026-Q2 | 2026-Q1 | 2025-Q4 | 2025-Q3 | 2025-Q2 | 2025-Q1 | 2024-Q4 | 2024-Q3 | 2024-Q2 | 2024-Q1 | 2023-Q4 | 2023-Q3 | 2023-Q2 | 2023-Q1 | 2022-Q4 | 2022-Q3 | 2022-Q2 | 2022-Q1 | 2021-Q4 | 2021-Q3 | 2021-Q2 | 2021-Q1 | 2020-Q4 | 2020-Q3 | 2020-Q2 | 2020-Q1 | 2019-Q4 | 2019-Q3 | 2019-Q2 | 2019-Q1 | 2018-Q4 | 2018-Q3 | 2018-Q2 | 2018-Q1 | 2017-Q4 | 2017-Q3 | 2017-Q2 | 2017-Q1 | 2016-Q4 | 2016-Q3 | 2016-Q2 | 2016-Q1 | 2015-Q4 | 2015-Q3 | 2015-Q2 | 2015-Q1 | 2014-Q4 | 2014-Q3 | 2014-Q2 | 2014-Q1 | 2013-Q4 | 2013-Q3 | 2013-Q2 | 2013-Q1 | 2012-Q4 | 2012-Q3 | 2012-Q2 | 2012-Q1 | 2011-Q4 | 2011-Q3 | 2011-Q2 | 2011-Q1 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 722 | 770 | 429 | 770 | 396 | - | 328 | 1.41 K | 758 | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 172 K | - | - | 217 K | 118 K | 208 K | - | 95.9 K | 123 K | - | - | 76.7 K | - | 89.7 K | - | - | 2.28 K | - | - | 1.57 K | 72.4 K | 3.07 K | 88.1 K | 56.4 K | 89.5 K | 79 K | 93.9 K | 85 K | 86.9 K | 86.3 K | 43.2 K | 12.9 K | 12.9 K | 10.4 M | 19.3 K | 14.7 M | 20.6 K | - | - |
All numbers in USD currency
Indicator range from quarterly reporting
| Maximum | Minimum | Average |
|---|---|---|
| 14.7 M | 328 | 772 K |
DPO Ratio of other stocks in the Biotechnology industry
| Issuer | DPO Ratio | Price | % 24h | Market Cap | Country | |
|---|---|---|---|---|---|---|
|
Happiness Biotech Group Limited
HAPP
|
5.06 K | - | 1.35 % | $ 17.8 M | ||
|
Dynavax Technologies Corporation
DVAX
|
52.8 | - | - | $ 2.02 B | ||
|
AgeX Therapeutics
AGE
|
5.24 K | - | -10.17 % | $ 12.2 K | ||
|
I-Mab
IMAB
|
2.24 K | - | - | $ 866 M | ||
|
Deciphera Pharmaceuticals
DCPH
|
2.2 K | - | - | $ 2.18 B | ||
|
Alexion Pharmaceuticals, Inc.
ALXN
|
78.2 | - | - | $ 40.3 B | ||
|
AstraZeneca PLC
AZN
|
265 | - | - | $ 96.9 B | ||
|
Midatech Pharma plc
MTP
|
162 | - | -18.52 % | $ 27.3 M | ||
|
Affimed N.V.
AFMD
|
2.52 K | - | -34.95 % | $ 21.5 M | ||
|
Институт стволовых клеток человека
ISKJ
|
115 | - | - | - | ||
|
Celyad Oncology SA
CYAD
|
55.8 K | - | - | $ 12.5 M | ||
|
Berkeley Lights
BLI
|
135 | - | -7.31 % | $ 87 M | ||
|
Celldex Therapeutics
CLDX
|
4.06 K | $ 31.82 | -0.95 % | $ 2.11 B | ||
|
Ayala Pharmaceuticals
AYLA
|
2.21 K | - | - | $ 7.46 M | ||
|
Cyclacel Pharmaceuticals
CYCCP
|
1.79 K | - | -4.36 % | $ 27 M | ||
|
Enlivex Therapeutics Ltd.
ENLV
|
981 | $ 0.62 | -5.89 % | $ 28.3 M | ||
|
Anika Therapeutics
ANIK
|
43.4 | $ 14.45 | -1.1 % | $ 207 M | ||
|
Advaxis
ADXS
|
85.6 K | - | -9.65 % | $ 45.9 M | ||
|
Esperion Therapeutics
ESPR
|
7.93 K | $ 3.17 | 0.48 % | $ 659 M | ||
|
Eton Pharmaceuticals
ETON
|
74.3 | $ 32.78 | 1.96 % | $ 882 M | ||
|
Aeterna Zentaris
AEZS
|
34.4 K | - | 5.93 % | $ 314 M | ||
|
AIkido Pharma
AIKI
|
1.92 | - | 1.93 % | $ 17.4 M | ||
|
Exelixis
EXEL
|
148 | $ 52.93 | -0.14 % | $ 14.4 B | ||
|
Albireo Pharma
ALBO
|
1.59 K | - | -0.23 % | $ 916 M |